BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >
WHO WE ARE

Management Team

Jeffrey Bailey, assumed the role of Chief Executive Officer in November 2020, after serving as interim CEO from May 2020 to November 2020. Mr. Bailey joined the Board of Directors in March 2020. Mr. Bailey has an accomplished record in leading both public and private healthcare companies where he has leveraged his diverse leadership experiences in various functional areas including commercial, supply chain and business development, as well as in-licensing and transactions. His experiences include a 20+ year career at Johnson & Johnson/Janssen Pharmaceuticals, a tenure as Operating Unit President at Novartis Pharmaceuticals, Chief Commercial Officer at King Pharmaceuticals, Chief Operating Officer at Fougera Pharmaceuticals, and Chairman and CEO of Neurovance. Mr. Bailey also served as President and CEO of Lantheus Medical Imaging, Inc, taking the company public in 2015. Most recently, he was the CEO of IlluminOss Medical, Inc, which was acquired.

Mr. Bailey has served as Chairman of Aileron Therapeutics since March 2018 and also serves as a board member for Tekla Capital Management. Mr. Bailey received a Bachelor of Science Degree from Rutgers University.

Mr. Plesha has served as President & Chief Commercial Officer for BDSI since he was elevated to the position in December 2017. Scott joined BDSI in August 2015, when he assumed the role of Senior Vice President of Sales & Marketing.

Before joining BDSI, Scott was a senior executive with Salix Pharmaceuticals, holding several significant leadership positions, including head of Gastroenterology Sales Force & Training. Scott played a critical role in building Salix’s commercial team into a leading gastroenterology sales force. During his tenure at Salix, he helped lead the successful launch or relaunch of more than 20 products, driving revenues from a startup commercial organization to $1.6 billion when the company was acquired in 2015. Scott was a member of the Executive Leadership Team and the Acquisitions and Integration Team at Salix.

Scott also assumed roles of increasing responsibility in specialty pharmaceutical companies, including Solvay Pharmaceuticals and Oclassen Pharmaceuticals, a division of Watson Laboratories. He has more than 20 years of experience leading commercial organizations and over 30 years of biopharma experience.

Mr. Plesha received his Bachelor of Arts in Pre-Medical Studies from DePauw University.

John Golubieski assumed the role of Chief Financial Officer in November 2021.

Mr. Golubieski brings a very broad level of experience as his career has progressed from PricewaterhouseCoopers to a 16-year career in various finance functions at Bristol-Myers Squibb before taking on senior level finance roles. These roles include Senior VP of Finance of King Pharmaceuticals, CFO at Fougera Pharmaceuticals and then onto Lantheus Medical Imaging as interim CFO setting the groundwork to take the company public with a successful IPO. Most recently, John served as the CFO of IlluminOss Medical, an orthopedic company that was acquired last year. Mr. Golubieski earned an MBA from Rider University as well as a Bachelor of Science degree in both Commerce and Accounting from Rider University.

Mr. Lockhart has been Senior Vice President, Operations for BDSI since January 2018. Prior to being elevated to this role, Joseph served as Vice President of Manufacturing and Supply Chain since joining BDSI in November 2015.

Over the course of his 35-year career in the pharmaceutical industry, Joseph has served in key management and leadership roles. He has extensive operational experience at both the technical and strategic levels, with a particular focus on supply-chain management, outsourcing, CMC (Chemistry, Manufacturing, and Controls), quality, cost efficiencies, and process improvements.

Prior to joining BDSI, Joseph served as Vice President, Pharmaceutical Development and Manufacturing at Salix Pharmaceuticals, where he provided strategic management of the company’s formulation development, manufacturing, clinical trial material, and technical operations. During his 15-year tenure at Salix, Joseph held positions of increasing responsibility and contributed to multiple successful NDA submissions, as well as product acquisitions and launches. Prior to his tenure at Salix, Joseph held various operational CMC-related positions with leading pharmaceutical organizations, including Merz Pharma and Baxter Healthcare.

Mr. Lockhart received a BA degree in Chemistry from the University of North Carolina at Chapel Hill. He earned his MBA degree from the University of North Carolina at Charlotte.

Mr. Ostrander has been SVP, Business Development since joining BDSI in January 2020.

Prior to joining BDSI, Kevin was head of North American Business Development for Glenmark Pharmaceuticals USA, where he successfully expanded the company's generic and brand business portfolios through key strategic partnerships. Before joining Glenmark, Kevin held positions of increasing responsibility in business development, licensing, and corporate development with Sandoz (division of Novartis), Eurand, Watson Pharmaceuticals, and Cardinal Health. He has closed more than 75 transactions, with total valuation exceeding $700 million, with domestic and international partners across a diverse range of therapeutic disease states. Kevin started his career as an R&D scientist, spending 10 years developing novel formulations and manufacturing processes for Sterling Drug, Nycomed, NanoSystems (division of Eastman Kodak), and Ѐlan Drug Delivery. He has published numerous scientific articles in peer-review journals, been an invited speaker at scientific conferences and the US Food and Drug Administration, and is an inventor with multiple US/international patents.

Kevin has nearly 30 years of experience in the biopharma industry with leading global organizations including Sandoz, Mylan, Cardinal Health, Ѐlan, and Nycomed. He has been involved in many functional business areas throughout the pharmaceutical industry, including project management, regulatory affairs, quality assurance, formulation design, technology transfer, device development, and strategic planning.

Mr. Ostrander received his BS degree in Biology from the State University of New York at Albany, and an MS degree in Pharmaceutical Quality Assurance and Regulatory Affairs from Temple University School of Pharmacy in Philadelphia, Pennsylvania. He earned his MBA in International Business at St. Joseph’s University in Philadelphia, Pennsylvania.

Dr. Smith has been Chief Medical Officer since joining BDSI in July 2018.

Prior to joining BDSI, Tom served as Chief Medical Officer for 3 companies, including Charleston Laboratories, Inc., Ameritox, LLC, and Mallinckrodt Pharmaceuticals. He provided executive oversight for the scientific, medical, and clinical aspects of each business. During his tenure, Dr. Smith successfully developed medical solutions to benefit patients living with chronic and complex diseases.

Tom has more than 2 decades of experience in the biopharma industry with leading global organizations including Teva Pharmaceuticals, Genzyme, and Abbott Laboratories. While primarily focused on central nervous system (CNS) disorders, Dr. Smith has also worked across therapeutic areas such as chronic kidney disease, women’s health, respiratory health, oncology, and endocrinology.

Prior to his career in the pharmaceutical industry, Tom was in private practice for 12 years, serving as a thought leader and clinical investigator for several medications indicated for the treatment of headache and migraine.

Dr. Smith earned a Doctor of Medicine degree from the Indiana University School of Medicine and a BS degree from Purdue University. He is a member of several medical societies and has published extensively throughout his career.

Mr. Vollins has been General Counsel, Chief Compliance Officer & Corporate Secretary since joining BDSI in November 2018.

Jim is a seasoned public-company and healthcare attorney, with decades of executive experience and a focus on scaling high-quality pharmaceutical companies. Prior to joining BDSI, Jim served as General Counsel, Chief Compliance Officer & Corporate Secretary for Bio Products Laboratory Limited, a global biologics manufacturer, where he served as member of the executive leadership team responsible for developing and executing corporate strategy.

During his 27-year legal career, Jim has held roles of increasing responsibility for a number of prominent pharmaceutical companies, including Grifols Inc., Talecris Biotherapeutics, Inc., and Pfizer Inc. Jim’s career highlights include several successful multibillion-dollar M&A transactions. Jim began his legal career as a commercial litigator. He has tried cases and argued appeals in state and federal courts throughout the United States.

Jim has a BA degree from Wesleyan University and a JD degree from Case Western Reserve University School of Law. He is a frequent lecturer on US healthcare law.

Management Team

Jeffrey Bailey, assumed the role of Chief Executive Officer in November 2020, after serving as interim CEO from May 2020 to November 2020. Mr. Bailey joined the Board of Directors in March 2020. Mr. Bailey has an accomplished record in leading both public and private healthcare companies where he has leveraged his diverse leadership experiences in various functional areas including commercial, supply chain and business development, as well as in-licensing and transactions. His experiences include a 20+ year career at Johnson & Johnson/Janssen Pharmaceuticals, a tenure as Operating Unit President at Novartis Pharmaceuticals, Chief Commercial Officer at King Pharmaceuticals, Chief Operating Officer at Fougera Pharmaceuticals, and Chairman and CEO of Neurovance. Mr. Bailey also served as President and CEO of Lantheus Medical Imaging, Inc, taking the company public in 2015. Most recently, he was the CEO of IlluminOss Medical, Inc, which was acquired.

Mr. Bailey has served as Chairman of Aileron Therapeutics since March 2018 and also serves as a board member for Tekla Capital Management. Mr. Bailey received a Bachelor of Science Degree from Rutgers University.

Mr. Plesha has served as President & Chief Commercial Officer for BDSI since he was elevated to the position in December 2017. Scott joined BDSI in August 2015, when he assumed the role of Senior Vice President of Sales & Marketing.

Before joining BDSI, Scott was a senior executive with Salix Pharmaceuticals, holding several significant leadership positions, including head of Gastroenterology Sales Force & Training. Scott played a critical role in building Salix’s commercial team into a leading gastroenterology sales force. During his tenure at Salix, he helped lead the successful launch or relaunch of more than 20 products, driving revenues from a startup commercial organization to $1.6 billion when the company was acquired in 2015. Scott was a member of the Executive Leadership Team and the Acquisitions and Integration Team at Salix.

Scott also assumed roles of increasing responsibility in specialty pharmaceutical companies, including Solvay Pharmaceuticals and Oclassen Pharmaceuticals, a division of Watson Laboratories. He has more than 20 years of experience leading commercial organizations and over 30 years of biopharma experience.

Mr. Plesha received his Bachelor of Arts in Pre-Medical Studies from DePauw University.

John Golubieski assumed the role of Chief Financial Officer in November 2021.

Mr. Golubieski brings a very broad level of experience as his career has progressed from PricewaterhouseCoopers to a 16-year career in various finance functions at Bristol-Myers Squibb before taking on senior level finance roles. These roles include Senior VP of Finance of King Pharmaceuticals, CFO at Fougera Pharmaceuticals and then onto Lantheus Medical Imaging as interim CFO setting the groundwork to take the company public with a successful IPO. Most recently, John served as the CFO of IlluminOss Medical, an orthopedic company that was acquired last year. Mr. Golubieski earned an MBA from Rider University as well as a Bachelor of Science degree in both Commerce and Accounting from Rider University.

Mr. Lockhart has been Senior Vice President, Operations for BDSI since January 2018. Prior to being elevated to this role, Joseph served as Vice President of Manufacturing and Supply Chain since joining BDSI in November 2015.

Over the course of his 35-year career in the pharmaceutical industry, Joseph has served in key management and leadership roles. He has extensive operational experience at both the technical and strategic levels, with a particular focus on supply-chain management, outsourcing, CMC (Chemistry, Manufacturing, and Controls), quality, cost efficiencies, and process improvements.

Prior to joining BDSI, Joseph served as Vice President, Pharmaceutical Development and Manufacturing at Salix Pharmaceuticals, where he provided strategic management of the company’s formulation development, manufacturing, clinical trial material, and technical operations. During his 15-year tenure at Salix, Joseph held positions of increasing responsibility and contributed to multiple successful NDA submissions, as well as product acquisitions and launches. Prior to his tenure at Salix, Joseph held various operational CMC-related positions with leading pharmaceutical organizations, including Merz Pharma and Baxter Healthcare.

Mr. Lockhart received a BA degree in Chemistry from the University of North Carolina at Chapel Hill. He earned his MBA degree from the University of North Carolina at Charlotte.

Dr. Smith has been Chief Medical Officer since joining BDSI in July 2018.

Prior to joining BDSI, Tom served as Chief Medical Officer for 3 companies, including Charleston Laboratories, Inc., Ameritox, LLC, and Mallinckrodt Pharmaceuticals. He provided executive oversight for the scientific, medical, and clinical aspects of each business. During his tenure, Dr. Smith successfully developed medical solutions to benefit patients living with chronic and complex diseases.

Tom has more than 2 decades of experience in the biopharma industry with leading global organizations including Teva Pharmaceuticals, Genzyme, and Abbott Laboratories. While primarily focused on central nervous system (CNS) disorders, Dr. Smith has also worked across therapeutic areas such as chronic kidney disease, women’s health, respiratory health, oncology, and endocrinology.

Prior to his career in the pharmaceutical industry, Tom was in private practice for 12 years, serving as a thought leader and clinical investigator for several medications indicated for the treatment of headache and migraine.

Dr. Smith earned a Doctor of Medicine degree from the Indiana University School of Medicine and a BS degree from Purdue University. He is a member of several medical societies and has published extensively throughout his career.

Mr. Vollins has been General Counsel, Chief Compliance Officer & Corporate Secretary since joining BDSI in November 2018.

Jim is a seasoned public-company and healthcare attorney, with decades of executive experience and a focus on scaling high-quality pharmaceutical companies. Prior to joining BDSI, Jim served as General Counsel, Chief Compliance Officer & Corporate Secretary for Bio Products Laboratory Limited, a global biologics manufacturer, where he served as member of the executive leadership team responsible for developing and executing corporate strategy.

During his 27-year legal career, Jim has held roles of increasing responsibility for a number of prominent pharmaceutical companies, including Grifols Inc., Talecris Biotherapeutics, Inc., and Pfizer Inc. Jim’s career highlights include several successful multibillion-dollar M&A transactions. Jim began his legal career as a commercial litigator. He has tried cases and argued appeals in state and federal courts throughout the United States.

Jim has a BA degree from Wesleyan University and a JD degree from Case Western Reserve University School of Law. He is a frequent lecturer on US healthcare law.

Mr. Ostrander has been SVP, Business Development since joining BDSI in January 2020.

Prior to joining BDSI, Kevin was head of North American Business Development for Glenmark Pharmaceuticals USA, where he successfully expanded the company's generic and brand business portfolios through key strategic partnerships. Before joining Glenmark, Kevin held positions of increasing responsibility in business development, licensing, and corporate development with Sandoz (division of Novartis), Eurand, Watson Pharmaceuticals, and Cardinal Health. He has closed more than 75 transactions, with total valuation exceeding $700 million, with domestic and international partners across a diverse range of therapeutic disease states. Kevin started his career as an R&D scientist, spending 10 years developing novel formulations and manufacturing processes for Sterling Drug, Nycomed, NanoSystems (division of Eastman Kodak), and Ѐlan Drug Delivery. He has published numerous scientific articles in peer-review journals, been an invited speaker at scientific conferences and the US Food and Drug Administration, and is an inventor with multiple US/international patents.

Kevin has nearly 30 years of experience in the biopharma industry with leading global organizations including Sandoz, Mylan, Cardinal Health, Ѐlan, and Nycomed. He has been involved in many functional business areas throughout the pharmaceutical industry, including project management, regulatory affairs, quality assurance, formulation design, technology transfer, device development, and strategic planning.

Mr. Ostrander received his BS degree in Biology from the State University of New York at Albany, and an MS degree in Pharmaceutical Quality Assurance and Regulatory Affairs from Temple University School of Pharmacy in Philadelphia, Pennsylvania. He earned his MBA in International Business at St. Joseph’s University in Philadelphia, Pennsylvania.

Board of Directors

Recent BDSI News

November 3, 2021

Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential

Read more
October 21, 2021

RALEIGH, N.C. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial

Read more
October 20, 2021

RALEIGH, N.C. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open of

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
November 29, 2021BDSI $2.82/ - -3.09%
Data provided by Nasdaq. Minimum 15 minutes delayed.